propylthiouracil- propylthiouracil tablet
west-ward pharmaceutical corp - propylthiouracil (unii: 721m9407iy) (propylthiouracil - unii:721m9407iy) - propylthiouracil 50 mg - propylthiouracil is indicated: - in patients with graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. - to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole. propylthiouracil is contraindicated in patients who have demonstrated hypersensitivity to the drug or any of the other product components.
propylthiouracil 50mg tablets
macleods pharma uk ltd - propylthiouracil - oral tablet - 50mg
propylthiouracil 50mg tablets
de pharmaceuticals - propylthiouracil - oral tablet - 50mg
propylthiouracil 50mg tablets
ivax pharmaceuticals uk ltd - propylthiouracil - oral tablet - 50mg
propylthiouracil 50mg tablets
kent pharma (uk) ltd - propylthiouracil - oral tablet - 50mg
propylthiouracil 50mg tablets
alliance healthcare (distribution) ltd - propylthiouracil - oral tablet - 50mg
propylthiouracil 50mg tablets
a a h pharmaceuticals ltd - propylthiouracil - oral tablet - 50mg
propylthiouracil 50mg tablets
wockhardt uk ltd - propylthiouracil - oral tablet - 50mg
propylthiouracil 50mg tablets
halewood chemicals ltd - propylthiouracil - oral tablet - 50mg
propylthiouracil tablet
actavis pharma, inc. - propylthiouracil (unii: 721m9407iy) (propylthiouracil - unii:721m9407iy) - propylthiouracil 50 mg - propylthiouracil tablets are indicated: - in patients with graves’ disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option - to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole propylthiouracil is contraindicated in patients who have demonstrated hypersensitivity to the drug or any of the other product components.